Felix Clinical Trial complete, Data Lock expected in 2 weeks
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Memphasys Ltd has announced the completion of the final patient visit in its Felix clinical trial, with data lock expected soon. The company is currently focused on data clean-up and verification to ensure the accuracy of the trial results before statistical analysis. Preliminary results are anticipated to be released in early March, which will support the CE Mark submission for market entry in Europe. This milestone is crucial for advancing regulatory approvals in other regions, including Australia and India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Memphasys
- Publication Highlights Diagnostic Potential of RoXsta TM
- Heranova Felix System Utilisation Testing commences in China
- Bovine Study commences to assess RoXsta antioxidant system
- Felix Clinical Registration Study completed, expanding mkt
- Letter of Intent with Heranova for Felix System Distribution
Later from Memphasys
- Leading Brazilian Andrology Clinic to test Felix System
- Felix Data lock complete and regulatory submission commenced
- Extension of Convertible Notes
- Half Yearly Report and Accounts
- Felix Trial Confirms Best-in-Class Performance
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys